UNSPSC 51162727: Guaifenesin

This classification denotes an expectorant with the molecular formula C10H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears US NIH Compound Identifier 3516. European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG.

UNSPSC 51162727 Guaifenesin, a Commodity code, encompasses pharmaceutical products and medical supplies purchased by state and local health and corrections agencies. State and local governments buy under this code primarily through health departments, corrections systems, and community health programs that stock medications and pharmaceutical products for patient care and public health initiatives. Recent solicitations show demand for both parenteral pharmaceutical products — including intravenous solutions, nutrition preparations, and injectable medications — and non-prescription pharmaceutical items such as naloxone and drug deactivation systems used in emergency response and community health programs. The issuing bodies include state departments of corrections and county health authorities, reflecting the breadth of agencies managing pharmaceutical inventory and medication distribution across correctional, clinical, and community settings.

The Washington State Department of Corrections posted RFQ RFQQK13020 on September 8, 2026, seeking parenteral products, services, and equipment for eight facilities across the state with a response deadline of October 7, 2026; the procurement includes parenteral nutrition solutions, intravenous solutions, and controlled substances with strict delivery requirements (24-hour turnaround for custom preparations, 8-hour delivery for standard supplies) and anticipates multiple awards across three regional zones. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to a community health building. Recent activity spans Washington and Florida; the code sees periodic but not continuous state and local procurement activity, with opportunities concentrated in corrections and public health agencies managing pharmaceutical supply chains and emergency response inventory.